Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | GNRHR | P30968 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176988 | 0.92 | GNRHR (0.48) | NPC1SMN1; SMN2ALDH1A1GFERGNRHR | |
| SCHEMBL418842 | 0.92 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1GFERGNRHRPPARG | |
| SCHEMBL421355 | 0.84 | GNRHR (0.48) | SMN1; SMN2ALDH1A1GFERGNRHRPPARG | |
| SCHEMBL421179 | 0.82 | GNRHR (0.43) | NPC1SMN1; SMN2GNRHRMAPTTP53 | |
| SCHEMBL12634807 | 0.81 | ACSS2 (0.46) | SMN1; SMN2GFERPPARGPOLBL3MBTL1 | |
| SCHEMBL13259056 | 0.80 | ALDH1A1 (0.43) | NPC1SMN1; SMN2ALDH1A1GFERGNRHR | |
| SCHEMBL11388072 | 0.80 | BRD4 (0.51) | SMN1; SMN2ALDH1A1GFERGNRHRMAPT | |
| SCHEMBL28230791 | 0.79 | SMN1; SMN2 (0.66) | NPC1SMN1; SMN2MAPTL3MBTL1TP53 | |
| SCHEMBL1183031 | 0.78 | SCD (0.44) | ALDH1A1 | |
| SCHEMBL6896313 | 0.78 | GNRHR (0.47) | ALDH1A1GFERGNRHRPPARGTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | NPC1 1876/4885SMN1; SMN2 991/4885ALDH1A1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.